The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 343:385-391 August 10, 2000 Number 6
NextNext

Coronary Stenting plus Platelet Glycoprotein IIb/IIIa Blockade Compared with Tissue Plasminogen Activator in Acute Myocardial Infarction
Albert Schömig, M.D., Adnan Kastrati, M.D., Josef Dirschinger, M.D., Julinda Mehilli, M.D., Ullrich Schricke, M.D., Jürgen Pache, M.D., Stefan Martinoff, M.D., Franz-Josef Neumann, M.D., Markus Schwaiger, M.D., for The Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Prevention of myocardial damage is the main goal of all reperfusion therapies in patients with acute myocardial infarction. The relative efficacy of various reperfusion strategies is under intensive investigation. We assessed whether coronary stenting combined with the blockade of platelet glycoprotein IIb/IIIa receptors produces a greater degree of myocardial salvage than fibrinolysis with an accelerated infusion of alteplase, a tissue plasminogen activator.

Methods A total of 140 patients were enrolled in the randomized trial; 71 were assigned to receive a stent plus abciximab, and 69 to receive intravenous alteplase. The primary end point was the degree of myocardial salvage, determined by means of serial scintigraphic studies with technetium Tc 99m sestamibi. The secondary end point was a composite of death, reinfarction, and stroke within six months after randomization.

Results In the group that received a stent plus abciximab, the median size of the final infarct was 14.3 percent of the left ventricle (25th and 75th percentiles, 6.8 and 24.5 percent), as compared with a median of 19.4 percent (25th and 75th percentiles, 7.9 and 34.2 percent) in the alteplase group (P=0.02). This difference was due to the larger salvage index (the percentage of the left ventricle that was salvaged, divided by the percentage that was compromised by the initial perfusion defect) in the stent group: 0.57 (25th and 75th percentiles, 0.35 and 0.69), as compared with 0.26 (25th and 75th percentiles, 0.09 and 0.61; P<0.001). The cumulative incidence of death, reinfarction, or stroke at six months was lower in the stent group than in the alteplase group (8.5 vs. 23.2 percent, P=0.02; relative risk, 0.34; 95 percent confidence interval, 0.13 to 0.88).

Conclusions In patients with acute myocardial infarction, coronary stenting plus abciximab leads to a greater degree of myocardial salvage and a better clinical outcome than does fibrinolysis with a tissue plasminogen activator.


Source Information

From the Deutsches Herzzentrum (A.S., A.K., J.D., J.M., S.M.), the 1. Medizinische Klinik rechts der Isar (A.S., J.P., F.-J.N.), and the Klinik und Poliklinik für Nuklearmedizin rechts der Isar (U.S., M.S.), Technische Universität, Munich, Germany.

Address reprint requests to Dr. Schömig at Deutsches Herzzentrum, Lazarettstr. 36, 80636 Munich, Germany, or at aschoemig{at}dhm.mhn.de.

Full Text of this Article


Related Letters:

Interstitial Pneumonitis Associated with Sirolimus Therapy in Renal-Transplant Recipients
Singer S. J., Tiernan R., Sullivan E. J., Morelon E., Stern M., Kreis H.
Extract | Full Text  
N Engl J Med 2000; 343:1815-1816, Dec 14, 2000. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.